JP2009523846A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523846A5
JP2009523846A5 JP2008552359A JP2008552359A JP2009523846A5 JP 2009523846 A5 JP2009523846 A5 JP 2009523846A5 JP 2008552359 A JP2008552359 A JP 2008552359A JP 2008552359 A JP2008552359 A JP 2008552359A JP 2009523846 A5 JP2009523846 A5 JP 2009523846A5
Authority
JP
Japan
Prior art keywords
cells
subject
composition
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552359A
Other languages
English (en)
Japanese (ja)
Other versions
JP5432527B2 (ja
JP2009523846A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/001746 external-priority patent/WO2007087292A2/en
Publication of JP2009523846A publication Critical patent/JP2009523846A/ja
Publication of JP2009523846A5 publication Critical patent/JP2009523846A5/ja
Application granted granted Critical
Publication of JP5432527B2 publication Critical patent/JP5432527B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008552359A 2006-01-23 2007-01-23 脳損傷及び疾患のｍａｐｃ治療 Expired - Fee Related JP5432527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76095106P 2006-01-23 2006-01-23
US60/760,951 2006-01-23
PCT/US2007/001746 WO2007087292A2 (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013150313A Division JP6338331B2 (ja) 2006-01-23 2013-07-19 脳損傷及び疾患のｍａｐｃ治療

Publications (3)

Publication Number Publication Date
JP2009523846A JP2009523846A (ja) 2009-06-25
JP2009523846A5 true JP2009523846A5 (cg-RX-API-DMAC7.html) 2010-03-11
JP5432527B2 JP5432527B2 (ja) 2014-03-05

Family

ID=40280746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552359A Expired - Fee Related JP5432527B2 (ja) 2006-01-23 2007-01-23 脳損傷及び疾患のｍａｐｃ治療

Country Status (9)

Country Link
EP (1) EP1981515B1 (cg-RX-API-DMAC7.html)
JP (1) JP5432527B2 (cg-RX-API-DMAC7.html)
AU (1) AU2007208367B2 (cg-RX-API-DMAC7.html)
CA (1) CA2642826C (cg-RX-API-DMAC7.html)
DK (1) DK1981515T3 (cg-RX-API-DMAC7.html)
ES (1) ES2420957T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ570614A (cg-RX-API-DMAC7.html)
PL (1) PL1981515T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007087292A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
JP5950577B2 (ja) * 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
WO2010028249A1 (en) * 2008-09-04 2010-03-11 Abt Holding Company Use of stem cells to prevent neuronal dieback
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
AU2011220721B2 (en) * 2010-02-25 2015-02-05 Case Western Reserve University Modulation of macrophage activation
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2714059B1 (en) 2011-06-01 2018-10-03 Celularity, Inc. Treatment of pain using placental stem cells
RU2016123361A (ru) * 2013-11-15 2017-12-20 Антродженезис Корпорейшн Композиции, включающие клетки плацентарного перфузата человека
CN105331583B (zh) * 2015-12-08 2019-01-29 广州医科大学附属第三医院 一种促进人诱导多能干细胞向神经元诱导分化的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
EP1491093B1 (en) 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003202988A1 (en) * 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells

Similar Documents

Publication Publication Date Title
JP2009523846A5 (cg-RX-API-DMAC7.html)
JP2009514979A5 (cg-RX-API-DMAC7.html)
Petrou et al. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis
JP6091422B2 (ja) チェックポイントキナーゼ１阻害剤とｗｅｅ１キナーゼ阻害剤の組み合わせ
Rühle et al. The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy‐induced toxicity
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
MX347359B (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
HRP20210901T1 (hr) Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice
Wan et al. Update on therapeutic mechanism for bone marrow stromal cells in ischemic stroke
PE20091184A1 (es) Formas de dosificacion farmaceutica
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP2322178A3 (en) Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
IL273188B (en) Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor
Papadopoulos et al. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
CA2519789A1 (en) Aplidine for multiple myeloma treatment
O'Neill et al. Immunotherapy of systemic lupus erythematosus
De Berardis et al. When clozapine fails: augmentation strategies in the management of clozapine-resistant schizophrenia
CA2855719C (en) Apoaequorin for reducing neuronal injury due to ischemia
ZA202308035B (en) Application of riluzole- and borneol-containing composition in preparation of medication for treating cerebrovascular diseases
AR068608A1 (es) Neramexano para el tratamiento de nistagmo
HRP20120912T1 (hr) Derivati kinolina kao antibakterijska sredstva
Cravedi et al. Low-dose rituximab for posttransplant recurrent membranous nephropathy
Nelson et al. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients
Schuster et al. Phase I trial of CG53135-05 to prevent mucositis in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT)